On August 3, 2023 Imugene Limited (ASX:IMU), a clinical stage immunooncology company, reported that its CF33 Oncolytic Virus technology will be featured at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), to be held in San Diego, USA on 1-5 November 2023 (Press release, Imugene, AUG 3, 2023, View Source [SID1234633684]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As one of the most prestigious immunotherapy events on the calendar, SITC (Free SITC Whitepaper) 2023 features cutting-edge research presentations by various experts, oral, and poster abstract presentations and various opportunities for networking and discussion with members of the oncology community.

The CF33 technology has been accepted for a Trial-in-Progress Poster titled: A Phase I Safety and Tolerability Study of VAXINIA (CF33-hNIS), a Novel Chimeric Oncolytic Poxvirus, Administered Intratumorally or Intravenously in Adults with Metastatic or Advanced Solid Tumors.
Abstract #: 730

Imugene will announce further details from this abstract closer to the time of the event. For more about SITC (Free SITC Whitepaper) 2023, please visit: View Source